专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4775483A Method to reduce plasma cholesterol 失效
标题翻译：降低血浆胆固醇的方法
公开(公告)号：US4775483A
公开(公告)日：1988-10-04
申请号：US908692
申请日：1986-09-18
申请人： Sailen S. Mookerjea , Arun Nagpurkar , Uday Saxena
发明人： Sailen S. Mookerjea , Arun Nagpurkar , Uday Saxena
IPC分类号： B01D15/00 , B01D15/08 , B01J20/32
CPC分类号： B01D15/3809 , B01J20/28004 , B01J20/3092 , B01J20/3204 , B01J20/3212 , B01J20/3246 , B01J20/3248 , B01J20/3251 , B01J20/3257 , B01J20/3259 , B01J20/3261 , B01J20/3274 , B01J20/3425 , B01J20/3475 , B01D15/3814 , B01D15/426 , B01J2220/58
摘要： Cholesterol in liquids such as blood plasma can be reduced by passing such liquids over an insoluble matrix such as agarose or treated glass beads to which is attached a C-reactive protein capable of binding cholesterol. An eluent such as sodium chloride or phosphorylcholine can be used to remove bound cholesterol and regenerate the insoluble matrix-C-reactive protein combination for re-use.
摘要翻译：通过将这样的液体通过不溶性基质例如琼脂糖或处理过的玻璃珠，可以降低液体如血浆中的胆固醇，其中附着有能够结合胆固醇的C-反应蛋白。洗脱液如氯化钠或磷酸胆碱可用于去除结合的胆固醇并再生不溶性基质-C反应蛋白组合以供重复使用。

2. 发明申请

US20130338199A1 Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease 审中-公开
标题翻译：用于还原淀粉样β肽42（AB42）的新型烟酸组合物生产和治疗阿尔茨海默病
公开(公告)号：US20130338199A1
公开(公告)日：2013-12-19
申请号：US13971151
申请日：2013-08-20
申请人： Uday Saxena , Venkateswarlu Akella
发明人： Uday Saxena , Venkateswarlu Akella
IPC分类号： C07D213/80
CPC分类号： C07D213/80 , A61K31/085 , A61K31/12 , A61K31/192 , A61K31/196 , A61K31/455 , A61K2300/00
摘要： The present invention discloses (1) phenolic ester hybrids of niacin with m-methoxy-p-hydroxy phenyl compounds like eugenol, vanillin, apocynin, ferulic acid, isoferulic acid and eugenol epoxide and (2) cocrystals of hybrids as above, particularly cocrystal of niacin-eugenol hybrid with cocrystal former like eugenol and oxalic acid (3) novel pharmaceutical compositions comprising a combination of niacin and one or more small molecule/potentiating agent like eugenol, curcumin, cinnamic acid, meclofenamic acid, and their use in the treatment of a disorder or a disease caused by excess production of amyloid beta peptide-42 (Aβ42), its deposition, accumulation, and plaque formation including Alzheimer's Disease, dementia and mild cognitive impairment as well as other neurodegenerative diseases such as Parkinson's Disease, Huntington's disease, multiple sclerosis, amytrophic lateral sclerosis and ischemic stroke.
摘要翻译：本发明公开了（1）烟酸与α-甲氧基对羟基苯基化合物如丁子香酚，香草醛，阿朴替林，阿魏酸，异钌酸和丁子香酚环氧化物的酚酯混合物和（2）上述杂合体的共晶体，特别是共晶体烟酸 - 丁子香酚与共晶体如丁子香酚和草酸的混合物（3）包含烟酸和一种或多种小分子/增效剂如丁子香酚，姜黄素，肉桂酸，甲氯芬那酸的组合的新型药物组合物及其在治疗由淀粉样β肽-42（Abeta42）的过量产生引起的疾病或疾病，其沉积，积累和斑块形成，包括阿尔茨海默氏病，痴呆和轻度认知障碍以及其他神经变性疾病如帕金森病，亨廷顿舞蹈病，多发性硬化，肌萎缩性侧索硬化和缺血性卒中。

3. 发明授权

US07268134B2 Medical devices employing triazine compounds and compositions thereof 失效
公开(公告)号：US07268134B2
公开(公告)日：2007-09-11
申请号：US10951305
申请日：2004-09-27
申请人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Rao Yeleswarapu , Manojit Pal , Jangalgar Tirupathy Reddy , Velagala Venkata Rama Murali Krishna Reddy , Sesha Sridevi Alluri , Potlapally Rajender Kumar , Gaddam Om Reddy
发明人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Rao Yeleswarapu , Manojit Pal , Jangalgar Tirupathy Reddy , Velagala Venkata Rama Murali Krishna Reddy , Sesha Sridevi Alluri , Potlapally Rajender Kumar , Gaddam Om Reddy
IPC分类号： A61M31/00 , A61F2/86 , C07D251/70 , C07D251/52 , C07D251/30 , A61K31/53 , A61P35/00
CPC分类号： A61K31/53 , C04B35/632 , C07D251/30 , C07D251/44 , C07D251/46 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/66 , C07D251/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D453/02 , C07D487/04 , C07F9/6521 , C07F9/65583
摘要： The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

4. 发明授权

US07173032B2 Methods and compositions of novel triazine compounds 失效
公开(公告)号：US07173032B2
公开(公告)日：2007-02-06
申请号：US10390485
申请日：2003-03-17
申请人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Karen A. Campbell
发明人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Karen A. Campbell
IPC分类号： C07D251/70 , C07D251/48 , C07D401/12 , C07D403/12 , A61K31/53 , A61P35/00
CPC分类号： C07D413/04 , A61K31/53 , C07D251/30 , C07D251/44 , C07D251/46 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/66 , C07D251/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D453/02 , C07D487/04 , C07F9/6521 , C07F9/65583
摘要： The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

5. 发明授权

US07163943B2 Methods and compositions of novel triazine compounds 失效
标题翻译：新型三嗪化合物的方法和组成
公开(公告)号：US07163943B2
公开(公告)日：2007-01-16
申请号：US10397968
申请日：2003-03-26
申请人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Rao Yeleswarapu , Manojit Pal , Jangalgar Tirupathy Reddy , Velagala Venkata Rama Murali Krishna Reddy , Bhatlapenumarthy Sesha Sridevi , Potlapally Rajender Kumar , Gaddam Om Reddy
发明人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Rao Yeleswarapu , Manojit Pal , Jangalgar Tirupathy Reddy , Velagala Venkata Rama Murali Krishna Reddy , Bhatlapenumarthy Sesha Sridevi , Potlapally Rajender Kumar , Gaddam Om Reddy
IPC分类号： C07D251/30 , C07D251/46 , C07D251/52 , C07D251/54 , A61K31/53
CPC分类号： A61K31/53 , C04B35/632 , C07D251/30 , C07D251/44 , C07D251/46 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/66 , C07D251/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D453/02 , C07D487/04 , C07F9/6521 , C07F9/65583
摘要： The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.
摘要翻译：本发明涉及包含治疗由炎性反应引起的病理生理状况的化合物的方法和组合物。特别地，本发明涉及抑制或阻断糖基化蛋白质产生内皮细胞中信号传导相关炎症反应诱导的化合物。本发明涉及抑制平滑肌增殖的化合物。特别地，本发明涉及通过调节HSPG例如Perlecan抑制平滑肌细胞增殖的化合物。本发明还涉及化合物用于治疗以平滑肌增生为特征的血管闭塞症状，例如再狭窄和动脉粥样硬化。

6. 发明申请

US20070004729A1 Methods and compositions of novel triazine compounds 审中-公开
公开(公告)号：US20070004729A1
公开(公告)日：2007-01-04
申请号：US11471099
申请日：2006-06-20
申请人： Richard Timmer , Christopher Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Yeleswarapu , Manojit Pal , Jangalgar Reddy , Velagala Venkata Rama Reddy , Sesha Alluri , Potlapally Kumar , Gaddam Reddy
发明人： Richard Timmer , Christopher Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Yeleswarapu , Manojit Pal , Jangalgar Reddy , Velagala Venkata Rama Reddy , Sesha Alluri , Potlapally Kumar , Gaddam Reddy
IPC分类号： A61K31/53 , C07D403/02 , C07D251/54
CPC分类号： A61K31/53 , C04B35/632 , C07D251/30 , C07D251/44 , C07D251/46 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/66 , C07D251/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D453/02 , C07D487/04 , C07F9/6521 , C07F9/65583
摘要： The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

7. 发明申请

US20050137196A1 Medical devices employing triazine compounds and compositions thereof 失效
公开(公告)号：US20050137196A1
公开(公告)日：2005-06-23
申请号：US10951316
申请日：2004-09-27
申请人： Richard Timmer , Christopher Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Yeleswarapu , Manojit Pal , Jangalgar Reddy , Velagala Venkata Krishna Reddy , Bhatlapenumarthy Sesha Sridevi , Potlapally Kumar , Gaddam Reddy
发明人： Richard Timmer , Christopher Alexander , Sivaram Pillarisetti , Uday Saxena , Koteswar Yeleswarapu , Manojit Pal , Jangalgar Reddy , Velagala Venkata Krishna Reddy , Bhatlapenumarthy Sesha Sridevi , Potlapally Kumar , Gaddam Reddy
IPC分类号： A61K31/53 , C07D251/44 , C07D251/46 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/66 , C07D251/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D453/02 , C07D487/04 , C07F9/6521 , C07F9/6558 , C07D251/18 , C07D43/02
CPC分类号： A61K31/53 , C04B35/632 , C07D251/30 , C07D251/44 , C07D251/46 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/66 , C07D251/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D453/02 , C07D487/04 , C07F9/6521 , C07F9/65583
摘要： The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

8. 发明授权

US08846721B2 Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) 有权
标题翻译：降低成本的组合 42生产及其在治疗阿尔茨海默病（AD）中的应用
公开(公告)号：US08846721B2
公开(公告)日：2014-09-30
申请号：US13574886
申请日：2011-01-22
申请人： Venkateswarlu Akella , Uday Saxena , Anji Reddy Kallam
发明人： Venkateswarlu Akella , Uday Saxena , Anji Reddy Kallam
IPC分类号： C07D401/06 , C07D213/56 , A61K31/44 , C07D213/82 , C07D213/80 , C07D401/12
CPC分类号： C07D213/82 , C07D213/56 , C07D213/80 , C07D401/06 , C07D401/12
摘要： Novel small molecule compounds for reduction of Aβ 42 production and for treatment of Alzheimer′s Disease and other neurodegenerative disorders, methods of making them and pharmaceutical compositions containing them are described.
摘要翻译：用于还原A和Bgr的新型小分子化合物描述了生产和治疗阿尔茨海默病和其他神经变性疾病，制备它们的方法和含有它们的药物组合物。

9. 发明授权

US07335656B2 Medical devices employing triazine compounds and compositions thereof 失效
标题翻译：使用三嗪化合物的医疗装置及其组合物
公开(公告)号：US07335656B2
公开(公告)日：2008-02-26
申请号：US11512863
申请日：2006-08-30
申请人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Sesha Sridevi Alluri , Koteswar Rao Yeleswarapu , Manojit Pal , Jangalgar Tirupathy Reddy , Velagala Venkata Rama Murali Krishna Reddy , Potlapally Rajender Kumar , Gaddam Om Reddy
发明人： Richard T. Timmer , Christopher W. Alexander , Sivaram Pillarisetti , Uday Saxena , Sesha Sridevi Alluri , Koteswar Rao Yeleswarapu , Manojit Pal , Jangalgar Tirupathy Reddy , Velagala Venkata Rama Murali Krishna Reddy , Potlapally Rajender Kumar , Gaddam Om Reddy
IPC分类号： A61M31/00 , A61F2/86 , C07D251/70 , C07D251/52 , C07D251/30 , A61P35/00
CPC分类号： A61K31/53 , C07D251/30 , C07D251/44 , C07D251/46 , C07D251/48 , C07D251/50 , C07D251/52 , C07D251/66 , C07D251/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D453/02 , C07D487/04 , C07F9/6521 , C07F9/65583
摘要： The present invention relates to methods, compounds, and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses, and is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention also relates to compounds that inhibit smooth muscle proliferation, for example, by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis. This invention also relates to medical devices, such as a stent, comprising a compound or composition of this invention disposed on or within the medical device.
摘要翻译：本发明涉及包含治疗由炎性反应引起的病理生理状况的化合物的方法，化合物和组合物，并且涉及抑制或阻断糖基化蛋白质产生内皮细胞中信号传导相关炎症反应诱导的化合物。本发明还涉及抑制平滑肌增殖的化合物，例如通过调节HSPG如Perlecan。本发明还涉及化合物用于治疗以平滑肌增生为特征的血管闭塞症状，例如再狭窄和动脉粥样硬化。本发明还涉及包括设置在医疗装置上或内部的本发明的化合物或组合物的医疗装置，例如支架。

10. 发明授权

US07183317B2 Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality 失效
标题翻译：提高血浆HDL胆固醇水平和提高HDL功能的化合物和方法
公开(公告)号：US07183317B2
公开(公告)日：2007-02-27
申请号：US10886927
申请日：2004-07-08
申请人： James A. Sikorski , Jayraz Luchoomun , Charles Q. Meng , Uday Saxena
发明人： James A. Sikorski , Jayraz Luchoomun , Charles Q. Meng , Uday Saxena
IPC分类号： A61K31/255 , C07C323/00 , C07C229/00
CPC分类号： G01N33/92 , C07C323/20 , G01N2500/00 , G01N2500/10 , G01N2800/044
摘要： It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.
摘要翻译：已经发现，普罗布考的某些选择的醚及其药学上可接受的盐或前药可用于增加循环HDL胆固醇。这些化合物还可以通过（a）增加胆固醇酯的清除率，（b）增加对肝细胞表面受体的HDL-粒子亲和力或（c）增加apoAI-HDL的半衰期来改善HDL功能。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式